

REFERENCE

1. De A. Pyridoxine-Dependent Epilepsy in Zebra fish Caused by. 2017;207:1501–18.
2. Yang Z, Yang X, Wu Y, Wang J, Zhang Y, Xiong H, et al. Clinical diagnosis, treatment, and ALDH7A1 mutations in pyridoxine-dependent epilepsy in three chinese infants. *PLoS One*. 2014;9:7–12.
3. Tseng LA, Teela L, Janssen MC, Bok LA, Willemsen MAAP, Neuteboom RF, et al. Pyridoxine-dependent epilepsy (PDE-ALDH7A1) in adulthood: A Dutch pilot study exploring clinical and patient-reported outcomes. *Mol Genet Metab Reports* [Internet]. 2022;31:100853. Available from: <https://doi.org/10.1016/j.ymgmr.2022.100853>
4. Kaminiów K, Pająk M, Pająk R, Paprocka J. Pyridoxine-Dependent Epilepsy and Antiquitin Deficiency Resulting in Neonatal-Onset Refractory Seizures. *Brain Sci*. 2022;12.
5. Kim EH, Shin J, Lee BK. Neonatal seizures: diagnostic updates based on new definition and classification. *Clin Exp Pediatr*. 2022;65:387–97.
6. Falsaperla R, Sciuto L, La Spina L, Sciuto S, Praticò AD, Ruggieri M. Neonatal seizures as onset of Inborn Errors of Metabolism (IEMs): from diagnosis to treatment. A systematic review. *Metab Brain Dis* [Internet]. 2021;36:2195–203. Available from: <https://doi.org/10.1007/s11011-021-00798-1>
7. Almannai M, Al Mahmoud RA, Mekki M, El-Hattab AW. Metabolic Seizures. *Front Neurol*. 2021;12.
8. van Karnebeek CDM, Sayson B, Lee JJY, Tseng LA, Blau N, Horvath GA, et al. Metabolic Evaluation of Epilepsy: A Diagnostic Algorithm With Focus on Treatable Conditions. *Front Neurol*. 2018;9.
9. Kim J, Pipitone Dempsey A, Kim SY, Gunay-Aygun M, Vernon HJ. An Atypical Presentation of Pyridoxine-Dependent Epilepsy Diagnosed with Whole Exome Sequencing and Treated with Lysine Restriction and Supplementation with Arginine and Pyridoxine. *Case Rep Genet*. 2022;2022:1–4.
10. Review G. ALDH7A1 - aldehyde dehydrogenase 5 family , member A1 Homo sapiens. 2013;8–11.
11. Gospe SM. Pyridoxine-Dependent Epilepsy – ALDH7A1 Summary Genetic counseling Diagnosis Suggestive Findings. 2023;1–24.
12. Coughlin CR, Swanson MA, Spector E, Meeks NJL, Kronquist KE, Aslamy M, et al. The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy. *J Inherit Metab Dis*. 2019;42:353–61.



13. Van Karnebeek CDM, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, Coughlin CR, et al. Pyridoxine-Dependent Epilepsy: An Expanding Clinical Spectrum. *Pediatr Neurol* [Internet]. 2016;59:6–12. Available from: <http://dx.doi.org/10.1016/j.pediatrneurol.2015.12.013>
14. Spagnoli C, Pavlidis E, Pisani F. Neonatal seizures therapy: We are still looking for the efficacious drug. *Ital J Pediatr* [Internet]. 2013;39:1. Available from: Italian Journal of Pediatrics
15. Hundallah K, Tabarki B. Treatable inherited metabolic epilepsies. *Neurosciences*. 2021;26:229–35.
16. Gospe SM, Hecht ST. Longitudinal MRI findings in pyridoxine-dependent seizures. *Neurology*. 1998;51:74–8.
17. Mills PB, Footitt EJ, Mills KA, Tuschl K, Aylett S, Varadkar S, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). *Brain*. 2010;133:2148–59.
18. Strijker M, Tseng LA, van Avezaath LK, Oude Luttikhuis MAM, Ketelaar T, Coughlin CR, et al. Cognitive and neurological outcome of patients in the Dutch pyridoxine-dependent epilepsy (PDE-ALDH7A1) cohort, a cross-sectional study. *Eur J Paediatr Neurol* [Internet]. 2021;33:112–20. Available from: <https://doi.org/10.1016/j.ejpn.2021.06.001>
19. Arnoldi K. Case Corner. *Am Orthopt J*. 2000;50:129–33.
20. Coughlin CR, Tseng LA, Abdenur JE, Ashmore C, Boemer F, Bok LA, et al. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α -aminoadipic semialdehyde dehydrogenase deficiency. *J Inherit Metab Dis*. 2021;44:178–92.
21. Kava MP, Bryant L, Rowe P, Lewis B, Greed L, Balasubramaniam S. Beneficial outcome of early dietary lysine restriction as an adjunct to pyridoxine therapy in a child with pyridoxine dependant epilepsy due to Antiquitin deficiency. *JIMD Rep*. 2020;54:9–15.
22. van Karnebeek CDM, Hartmann H, Jaggumantri S, Bok LA, Cheng B, Connolly M, et al. Lysine restricted diet for pyridoxine-dependent epilepsy: First evidence and future trials. *Mol Genet Metab* [Internet]. 2012;107:335–44. Available from: <http://dx.doi.org/10.1016/j.yimgme.2012.09.006>

I. Laboratory Exam

a. Complete blood count

Parameter	15 July 2023	Reference Range
Leukocyte (x10 ³ /uL)	10.8	5.0 – 21.0
Erythrocyte (x10 ⁶ /uL)	5.53	4.0 - 5.60
Hemoglobin (g/dL)	19.1	15.0 – 19.60
Hematocrite (%)	56.4	46.0 – 62.0
MCV (fL)	102	95.0 – 115.0
MCH (pg)	34.5	30.0 – 42.0
MCHC (g/dL)	33.9	30.0 – 34.0
Platelet (x10 ³ uL)	308	150 - 450
Neutrophil (%)	33.3	30.0 - 60.0
Lymphocyte (%)	49.8	30.0 - 62.0
Monocyte (%)	11.3	4.0 - 17.0
Eosinophil (%)	5.3	1.0 - 5.0
Basophil (%)	0.3	0.0 - 2.0

b. Blood Chemistry

Parameter	15 July 2023	Reference Range
Natrium (mmol/L)	131	136 - 145
Kalium (mmol/L)	5.2	3.50 - 5.10
Chloride (mmol/L)	97	97 - 107
Calcium (mmol/L)	2.41	2.2 - 2.7
Magnesium (mg/dl)	2.3	1.5 - 2.2
Phosphat (mg/dl)	5	3.9 - 6.9
Glucose (mg/dl)	81	60 - 180
SGOT (mg/dL)	43.2	10 – 50
SGPT (mg/dL)	17	10 – 50
Ammonia (µg/dL)	75.6	27.2- 102

c. Urinalysis

Parameter	16 July 2023	Reference Range
Keton	Negative	Negative